Compare HTCR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | CMMB |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 9.1M |
| IPO Year | 2022 | 2023 |
| Metric | HTCR | CMMB |
|---|---|---|
| Price | $0.25 | $1.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 362.4K | 68.7K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 51.18% | N/A |
| EPS Growth | 66.67 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | ★ N/A | $49.25 |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.22 | $0.87 |
| 52 Week High | $1.66 | $3.86 |
| Indicator | HTCR | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 60.10 |
| Support Level | $0.25 | $1.48 |
| Resistance Level | $0.30 | $2.24 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 31.30 | 91.91 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.